Effect of Aspirin Dose on Mortality and Cardiovascular Events in People with Diabetes: A Meta-Analysis

  • Scot H. Simpson
  • John-Michael Gamble
  • Laurie Mereu
  • Thane Chambers



Pharmacologic evidence suggests adequate antiplatelet activity in diabetic patients requires >100 mg aspirin daily, yet recent trials have used ≤100 mg daily. This meta-analysis explored the relationship between aspirin dose and prevention of cardiovascular events.

Data Sources

Six electronic databases were searched using database-appropriate terms for aspirin, diabetes, and comparative study from inception until February 2010.

Review Methods

Randomized controlled trials and cohort studies comparing aspirin to no antiplatelet therapy were included if they reported cardiovascular events as pre-specified outcomes, aspirin dose, and number of diabetic patients. Studies were stratified by daily aspirin dose (≤100 mg; 101–325 mg; >325 mg) and pooled risk ratios (RR) were calculated using random effects models. All-cause mortality was the primary outcome of interest. Cardiovascular-related mortality, myocardial infarction, and stroke were secondary outcomes.


Data for diabetic patients were available from 21 studies (n = 17,522). Overall, 1,172 (15.4%) of 7,592 aspirin users and 1,520 (18.4%) of 8,269 controls died (p = 0.31). The pooled RRs were 0.89 (95% CI: 0.72–1.10; p = 0.27) from 13 studies using ≤100 mg (I2 = 64%); 0.89 (95% CI: 0.61–1.30; p = 0.55) from four studies using 101–325 mg (I2 = 83%); and 0.96 (95% CI: 0.85–1.08; p = 0.50) from eight studies using >325 mg (I2 = 0%). Aspirin use was associated with a significantly lower risk of mortality (RR: 0.82; 95% CI: 0.69–0.98; p = 0.03) in 13 secondary prevention studies (I2 = 27%), whereas aspirin use in seven primary prevention studies (I2 = 0%) was not (RR: 1.01; 95% CI 0.85–1.19; p = 0.94). A substantial amount of heterogeneity was observed amongst studies in all outcomes. Although inclusion of cohort studies was a major source of heterogeneity, stratification by study design did not reveal a significant dose-response relationship.


This summary of available data does not support an aspirin dose-response effect for prevention of cardiovascular events in diabetic patients. However, the systematic review identified an important gap in randomized controlled trial evidence for using 101–325 mg aspirin daily in diabetes.


aspirin diabetes mortality myocardial infarction stroke 

Supplementary material

11606_2011_1757_MOESM1_ESM.pdf (124 kb)
(PDF 123 kb)


  1. 1.
    Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Vascular protection in people with diabetes. Can J Diabetes. 2008;32(suppl 1):S102–S106.Google Scholar
  2. 2.
    Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30(1):162–172.PubMedCrossRefGoogle Scholar
  3. 3.
    Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.PubMedCrossRefGoogle Scholar
  4. 4.
    Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308(6921):81–106.Google Scholar
  5. 5.
    Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71–86.Google Scholar
  6. 6.
    Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321(3):129–135.Google Scholar
  7. 7.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–1762.PubMedCrossRefGoogle Scholar
  8. 8.
    Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264–3272.PubMedCrossRefGoogle Scholar
  9. 9.
    Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268(10):1292–1300.Google Scholar
  10. 10.
    Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285(19):2486–2497.Google Scholar
  11. 11.
    Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134–2141.PubMedCrossRefGoogle Scholar
  12. 12.
    Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.PubMedCrossRefGoogle Scholar
  13. 13.
    Welin L, Wilhelmsen L, Bjornberg A, Oden A. Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study. Pharmacoepidemiol Drug Saf. 2009;18(12):1143–1149.PubMedCrossRefGoogle Scholar
  14. 14.
    Leung WY, So WY, Stewart D, et al. Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients–a longitudinal observational study. Cardiovascular Diabetology. 2009;8:57.PubMedCrossRefGoogle Scholar
  15. 15.
    Colwell JA. Does aspirin use reduce cardiovascular risk in diabetes? Nat Rev Endocrinol. 2009;5(4):188–190.PubMedCrossRefGoogle Scholar
  16. 16.
    Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. Diabetes Care. 2010;33(6):1395–1402.PubMedCrossRefGoogle Scholar
  17. 17.
    De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.PubMedCrossRefGoogle Scholar
  18. 18.
    Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–1860.PubMedCrossRefGoogle Scholar
  19. 19.
    Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2010;87(2):211–218.PubMedCrossRefGoogle Scholar
  20. 20.
    Younis N, Williams S, Ammori B, Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother. 2010;11(9):1459–1466.PubMedCrossRefGoogle Scholar
  21. 21.
    Stavrakis S, Stoner JA, Azar M, Wayangankar S, Thadani U. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci. 2011;341(1):1–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336(7637):195–198.PubMedCrossRefGoogle Scholar
  23. 23.
    Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis. 2009;52(2):141–152.PubMedCrossRefGoogle Scholar
  24. 24.
    Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia. 2008;51(3):385–390.PubMedCrossRefGoogle Scholar
  25. 25.
    Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007;153(2):175–181.PubMedCrossRefGoogle Scholar
  26. 26.
    Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB. Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol. 2006;97(4):567–570.PubMedCrossRefGoogle Scholar
  27. 27.
    Fateh-Moghadam S, Plockinger U, Cabeza N, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005;42(2):99–103.PubMedCrossRefGoogle Scholar
  28. 28.
    Dichiara J, Bliden KP, Tantry US, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes. 2007;56(12):3014–3019.PubMedCrossRefGoogle Scholar
  29. 29.
    Law EH, Simpson SH. Aspirin use rates in diabetes: a systematic review and cross-sectional study. Can J Diabetes. 2010;34(3):211–217.Google Scholar
  30. 30.
    Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384.PubMedCrossRefGoogle Scholar
  31. 31.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.PubMedCrossRefGoogle Scholar
  32. 32.
    Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75(1):40–47.PubMedCrossRefGoogle Scholar
  33. 33.
    Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95(10):1218–1222.PubMedCrossRefGoogle Scholar
  34. 34.
    Ray WA. Observational studies of drugs and mortality. N Engl J Med. 2005;353(22):2319–2321.PubMedCrossRefGoogle Scholar
  35. 35.
    Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(Suppl 2):S14–S21.PubMedCrossRefGoogle Scholar
  36. 36.
    Jansson SP, Andersson DK, Svardsudd K. Mortality trends in subjects with and without diabetes during 33 years of follow-up. Diabetes Care. 2010;33(3):551–556.PubMedCrossRefGoogle Scholar
  37. 37.
    Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13.PubMedCrossRefGoogle Scholar
  38. 38.
    Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–1304.PubMedCrossRefGoogle Scholar
  39. 39.
    Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991;338(8779):1345–1349.Google Scholar
  40. 40.
    Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175–179.PubMedCrossRefGoogle Scholar
  41. 41.
    Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261(3):276–284.PubMedCrossRefGoogle Scholar
  42. 42.
    Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–848.PubMedCrossRefGoogle Scholar
  43. 43.
    Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54(12):1044–1054.PubMedCrossRefGoogle Scholar
  44. 44.
    Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed). 1988;296(6618):313–316.CrossRefGoogle Scholar
  45. 45.
    Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979;2(8156–8157):1313–1315.PubMedCrossRefGoogle Scholar
  46. 46.
    Aspirin in coronary heart disease. The Coronary Drug Project Research Group. J Chronic Dis. 1976;29(10):625–642.CrossRefGoogle Scholar
  47. 47.
    Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313(22):1369–1375.PubMedCrossRefGoogle Scholar
  48. 48.
    Feringa HH, Bax JJ, Karagiannis SE, et al. Elderly patients undergoing major vascular surgery: risk factors and medication associated with risk reduction. Arch Gerontol Geriatr. 2009;48(1):116–120.PubMedCrossRefGoogle Scholar
  49. 49.
    McAlister FA, Ghali WA, Gong Y, Fang J, Armstrong PW, Tu JV. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation. 2006;113(22):2572–2578.PubMedCrossRefGoogle Scholar
  50. 50.
    Cubbon RM, Gale CP, Rajwani A, et al. Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes Care. 2008;31(2):363–365.PubMedCrossRefGoogle Scholar
  51. 51.
    Ong G, Davis TM, Davis WA. Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study. Diabetes Care. 2010;33(2):317–321.PubMedCrossRefGoogle Scholar
  52. 52.
    Zanchetti A. Aspirin and Antiplatelet Drugs in the Prevention of Cardiovascular Complications of Diabetes. In: Morgensen CE, ed. Pharmacotherapy of diabetes: new developments. New York: Springer; 2007:211–218.CrossRefGoogle Scholar
  53. 53.
    Cochrane Handbook for Systematic Reviews of Interventions. 5.0.2 [updated September 2009] ed. The Cochrane Collaboration; 2008.Google Scholar
  54. 54.
    Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351(9098):233–241.Google Scholar
  55. 55.
    Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol. 2002;55(1):86–94.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2011

Authors and Affiliations

  • Scot H. Simpson
    • 1
  • John-Michael Gamble
    • 2
  • Laurie Mereu
    • 3
  • Thane Chambers
    • 4
  1. 1.Faculty of Pharmacy & Pharmaceutical Sciences3126 Dentistry / Pharmacy Centre, University of AlbertaEdmontonCanada
  2. 2.School of Public HealthUniversity of AlbertaEdmontonCanada
  3. 3.Faculty of Medicine & DentistryUniversity of AlbertaEdmontonCanada
  4. 4.University of Alberta Library ServicesEdmontonCanada

Personalised recommendations